Avoro Capital Advisors 13F: Adds $34M to RVMD Stake

Avoro Capital Advisors Increases Biotech Holding

Avoro Capital Advisors expanded its investment in Revolution Medicines, Inc. (NASDAQ: RVMD) by 8.03889400921659% during the period ending May 15, 2026, according to its latest Form 13F filing with the Securities and Exchange Commission. The fund acquired 174,444 additional shares of the Redwood City, California-based clinical-stage oncology company. Following these transactions, Avoro Capital Advisors held 2,344,444 shares of Revolution Medicines.

At the close of the reporting period, the fund's total position in the biotechnology firm was valued at $451,586,791.83. This is up from its previous position of 2,170,000 shares. Because 13F filings are backward-looking documents, these numbers reflect the fund's portfolio as of mid-May and do not account for any subsequent market transactions or portfolio adjustments.

Revolution Medicines Stock Performance

On Saturday, the stock was valued at $192.62 per share. The company's stock has seen significant upward momentum, trading far higher than its 52-week low of $42.18, though it remains below its 52-week high of $224.31. The stock's current level is positioned just below its 50-day moving average of $199.22, but represents substantial growth when compared to its longer-term 200-day moving average of $140.41. Revolution Medicines currently has a market capitalization of $41.32 billion.

Insider Buying and Selling at Revolution Medicines, Inc.

Several key company insiders have engaged in stock trades following the end of the 13F reporting period. Chief Financial Officer Jack Anders executed a transaction on June 24, 2026, selling 20,000 shares at an average price of $168.33 for a total value of $3,366,642.00 under a pre-arranged trading plan. On the exact same day, Anders acquired 20,000 shares at no cost. Earlier in the month, on June 16, 2026, the CFO also sold 2,722 shares at an average price of $156.12, totaling $424,958.64. Other corporate insiders, including Sushil Patel, Flavia Borellini, and Lorence Kim, each acquired shares on June 18, 2026, through transactions valued at $0.00.

Wall Street Analysts Maintain Buy Ratings

Financial analysts have recently issued several positive updates on the biotechnology firm. On October 16, 2026, William Blair initiated coverage on the company with an Outperform rating. On October 15, 2026, Needham reiterated its Buy rating with a $275.00 price target. RBC Capital maintained its Outperform rating on October 14, 2026, while nudging its target up to $260.00, following an earlier target raise to $259.00 on October 8, 2026. Truist Securities maintained its Buy rating on October 7, 2026, with a target of $240.00. Brookline Capital initiated coverage on September 28, 2026, with a Buy rating and a $318.00 target, while B of A Securities lifted its target to $265.00 on September 21, 2026. Morgan Stanley also initiated coverage on September 10, 2026, with an Overweight rating and a $255.00 target. The consensus among twenty analysts is a Strong Buy, with an average price target of $253.21.

Oncology Research Focus

Revolution Medicines focuses on discovering and developing targeted therapies for patients suffering from difficult-to-treat, RAS-addicted cancers. The company is actively moving multiple drug candidates through clinical trials, focusing on combination therapies that can suppress the pathways that allow cancer cells to survive and grow.

What's Ahead for Revolution Medicines, Inc.

Market participants will be watching the oncology developer closely as it prepares to report its next quarterly financial results on November 4, 2026. These upcoming earnings figures, along with future institutional filings, will provide clearer insight into whether large investors continue to back the company's clinical research pipeline.